During transition

Positive, consistent and tailored communication is imperative to a successful patient transition.

Patient archetypes

In addition to considering a patient’s disease activity and comorbidities – when transitioning a patient to a biosimilar you must also take into account the diversity of patients. Throughout the day we are sure you adapt how you talk to your patients based on their personalities. Similarly, when it comes to transitioning a patient to a biosimilar, you may want to consider situational language based on that patient’s personality. For that purpose, the below videos separate patients into three broad groups or types.

They are:


Dos and Don’ts

Dos of the follower patients:

The patient needs to feel well-treated, respected and safe in the medication the doctors suggest.

Manuscript

Manuscript

Dos of the investigative patients:

The patient needs assurance that they can lead a good-life, that they are well informed and that the medication is safe.

Dos of the busy patients:

The patient’s concerns and their desire to go into depth needs to be taken seriously. Affirm and provide relevant information.

Manuscript


Manuscript

The don’ts of talking transition

Words matter. Everyone who interacts with patients should pay special attention to their verbal and non-verbal communication. No “nocebo language”.


Patient Materials

The European Commission has published improved information for patients on biosimilar medicines. The Q&A are available in 7 languages (English, French, German, Italian, Polish, Portuguese and Spanish) offering patients access to unbiased and reliable information.